Teva To Sue FDA Over Pravachol Marketing Exclusivity

Law360, New York (July 6, 2005, 12:00 AM EDT) -- Israeli drug maker Teva Pharmaceutical Industries Ltd. said Wednesday it would sue the U.S. Food and Drug Administration over a decision that effectively wiped out the company’s marketing exclusivity for a generic version of Bristol-Myers Squibb Co.'s cholesterol medication Pravachol.

Teva said it strongly disagreed with the FDA ruling, which determined that the 180-day exclusivity period for generic versions Pravachol began on August 22, when another generic drug maker's lawsuit against Bristol-Myers was dismissed.

In that case, Canadian drug maker Apotex Inc. had sought a declaratory...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.